© catalin - stock.adobe.com

Pierre Fabre Laboratories, a leading French medical and beauty care company and Vernalis (R&D) Ltd, a fully owned subsidiary of HitGen Inc. and a specialist in drug discovery announce a long-term partnership for oncology drug discovery.

Picture: ©BioLizard

Depending on who you talk to, artificial intelligence (AI) is either a saviour or an enslaver. The concerns range from loss of jobs through to robots running society. However, in the life sciences, the use of AI and machine learning (ML) have created some excitement over their potential applications.

Ion Arocena; General Manager Asebio; © Asebio

Biotechnology is helping us tackle challenges such as emerging diseases, the impact of ageing in healthcare, population growth, climate change, and the green transition of the economy. Precision medicines, advanced therapies, mRNA and gene editing technologies are transforming the way diseases can be diagnosed and treated, providing life-saving solutions. Biotechnology is also at the forefront of building a sustainable economy, developing better crops, providing new protein sources, and producing bio-based materials.

© www.istockphoto.com/Firstsignal

University of Sheffield spinout gets £5m for gene therapies targeting ALS and FTD, advancing towards clinical trials.

©NicoElNino - stock.adobe.com

Oxford Biomedica’s proposed acquisition of ABL Europe from Institut Mérieux, at a consideration of €15m propels global leadership in cell and gene therapy.

© manfredrichter - pixabay.com

Austrian Kern Tec GmbH has raised €12m in the biggest Series A  financing ever seen for a foodtech company in Austria to scale food production from waste.

Picture: © Cavan Images / Westend61

Austria has gained an outstanding reputation as a research location in the field of life sciences both as a vibrant hub for science and as a cluster for research-oriented and manufacturing companies. The ABA links international companies with this ecosystem

© BenevolentAI Ltd

British drug discovery specialist BenevolentAI Ltd has licenced its end-to-end AI platform capabilities to Merck KGaA to deliver novel drug candidates for three targets in oncology, neurology and immunology.
 

Anti-CD45RC Abs suppresses the acute immune response by causing the death of harmful CD45RC+ T cells driving (severe) disease in patients. © Aborleris Pharma SA (Zoersel, Nantes

Autoimmunity specialist AbolerIS Pharma will use a €27.3m Series A Financing to advance its first-in-class antibody inducing immune tolerance in rheumatoid arthritis into the clinic.

© Shutterbug75 - pixabay.com

The Cultivated B ist the first company in the world to apply for EU-Novel-Food authorisation of a hotdog made from plant protein and cultivated muscle cells.